1. Home
  2. CRTO vs GPCR Comparison

CRTO vs GPCR Comparison

Compare CRTO & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Criteo S.A.

CRTO

Criteo S.A.

HOLD

Current Price

$20.40

Market Cap

1.1B

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$69.98

Market Cap

1.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRTO
GPCR
Founded
2005
2016
Country
France
United States
Employees
N/A
N/A
Industry
Advertising
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2013
2023

Fundamental Metrics

Financial Performance
Metric
CRTO
GPCR
Price
$20.40
$69.98
Analyst Decision
Buy
Strong Buy
Analyst Count
9
8
Target Price
$38.67
$69.57
AVG Volume (30 Days)
471.4K
2.2M
Earning Date
10-29-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
83.79
N/A
EPS
3.00
N/A
Revenue
$1,956,800,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.42
N/A
P/E Ratio
$7.01
N/A
Revenue Growth
0.53
N/A
52 Week Low
$19.00
$13.22
52 Week High
$47.27
$94.90

Technical Indicators

Market Signals
Indicator
CRTO
GPCR
Relative Strength Index (RSI) 49.13 85.42
Support Level $19.00 $30.94
Resistance Level $21.48 $36.09
Average True Range (ATR) 0.78 5.95
MACD 0.08 1.87
Stochastic Oscillator 56.45 61.04

Price Performance

Historical Comparison
CRTO
GPCR

About CRTO Criteo S.A.

Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: